Clostridium difficile infection laboratory findings

Revision as of 15:09, 10 December 2012 by Michael Maddaleni (talk | contribs)
Jump to navigation Jump to search

Clostridium difficile Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Clostridium difficile from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Abdominal X Ray

CT

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Clostridium difficile infection laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Clostridium difficile infection laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Clostridium difficile infection laboratory findings

CDC on Clostridium difficile infection laboratory findings

Clostridium difficile infection laboratory findings in the news

Blogs on Clostridium difficile infection laboratory findings

Directions to Hospitals Treating Clostridium difficile

Risk calculators and risk factors for Clostridium difficile infection laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Laboratory Findings

Cytotoxicity assay

C. difficile toxin detection as cytopathic effect in cell culture, and neutralized with specific anti-sera is the practical gold standard for studies investigating new CDAD diagnostic techniques. Toxigenic culture, in which organisms are cultured on selective medium and tested for toxin production remains the gold standard and is the most sensitive and specific test, although it is slow and labour-intensive.[1]

Enzyme-linked immunoabsorbant assay (ELISA) for toxin

Assessment of the A and B toxins by enzyme-linked immunoabsorbant assay (ELISA) for toxin A or B (or both) has:

At a prevalence of 15%, this leads to:

Experts recommend sending as many as three samples to rule-out disease if initial tests are negative. C. difficile toxin should clear from the stool of previously infected patients if treatment is effective.

Unfortunately, many hospitals only test for the prevalent toxin A. Strains that express only the B toxin are now present in many hospitals and ordering both toxins should occur. Not testing for both may contribute to a delay in obtaining laboratory results, which is often the cause of prolonged illness and poor outcomes.

Other Stool Tests

Stool leukocyte measurements and stool lactoferrin levels have also been proposed as diagnostic tests, but may have limited diagnostic accuracy.[2]

Routine Laboratory Findings

References

  1. Murray PR, Baron EJ, Pfaller EA, Tenover F, Yolken RH (editors) (2003). Manual of Clinical Microbiology (8th ed ed.). Washington DC: ASM Press. ISBN 1-55581-255-3 Check |isbn= value: checksum (help).
  2. Vaishnavi C, Bhasin D, Kochhar R, Singh K (2000). "Clostridium difficile toxin and faecal lactoferrin assays in adult patients". Microbes Infect. 2 (15): 1827–30. PMID 11165926.

Template:WH Template:WS